

RECEIVED

MAY 21 2003

Patent Application 09/528,978  
Attorney Docket  
No. PC10244A

CPA

TECH CENTER 1600/2900

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail to Addressee" service under 37 CFR 1.10 on April 30, 2003 and is addressed to Commissioner for Patents, Customer Service Center, Washington, DC 20231.

By

(Signature of person mailing)

Andrea E. Dorigo

Reg. No. 47,532

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: R. S. Obach

APPLICATION NO: 09/528,798

Examiner: S. Jiang

FILING DATE: March 21, 2000

Group Art Unit: 1617

TITLE: USE OF CYP2D6 INHIBITORS IN  
COMBINATION THERAPIESCommissioner for Patents  
Customer Service Center  
Washington, D.C. 20231

Sir:

RECEIVED

OCT 15 2003

TECH CENTER 1600/2900

**REQUEST FOR CORRECTED FILING RECEIPT**

Applicant requests that the filing receipt for the above identified application be corrected to change the section entitled Domestic Priority data as claimed by applicant, the to read:

- -This application claims benefit from Application No. 60/128,136, filed 4/7/99 --

Respectfully submitted,

Date:

April 30, 2003

Andrea Dorigo

Attorney for Applicant(s)

Reg. No. 47,532

Pfizer, Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5612  
(212) 733-1898



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE



RECEIVED  
MAY 21 2003  
TECH CENTER 1600/2900

COPY

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/528,978	03/21/2000	1617	726	PC10244A		22	2


CONFIRMATION NO. 7527

CORRECTED FILING RECEIPT



\*OC000000009888946\*

23913  
PFIZER INC  
150 EAST 42ND STREET  
5TH FLOOR - STOP 49  
NEW YORK, NY 10017-5612



Date Mailed: 04/23/2003

Receipt is acknowledged of a CPA in this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

R. Scott Obach, Gales Ferry, CT;

**Domestic Priority data as claimed by applicant**

-- This application claims benefit from Application No.  
60/128,136 filed 4/7/99 --

**Foreign Applications**

If Required, Foreign Filing License Granted: 05/30/2000

CPA filed on: 02/14/2003

Projected Publication Date: 07/31/2003

Non-Publication Request: No

Early Publication Request: No

**Title**

Use of CYP2D6 inhibitors in combination therapies

Preliminary Class

RECEIVED  
OCT 15 2003  
TECH CENTER 1600/2900